Source comparison
MK-677 Sleep vs Pharmaceutical Sleep Aids: Research Comparison
Slow-Wave Sleep Duration +50% vs baseline −15% vs baseline No significant change +10% vs baseline MK-677 produces the largest SWS increase without REM suppression. The only compound in this comparison that enhances rather than disrupts natural sleep architectu
This comparison does not assign a generated winner or score.
- Slow-Wave Sleep Duration
- +50% vs baseline
- −15% vs baseline
- No significant change
- +10% vs baseline
- MK-677 produces the largest SWS increase without REM suppression. The only compound in this comparison that enhances rather than disrupts natural sleep architecture
- REM Sleep Percentage
- Preserved (20–25%)
- Reduced to 12–15%
- Preserved
- Reduced to 15–18%
- Zolpidem and trazodone suppress REM rebound, which impairs memory consolidation. MK-677 maintains normal REM cycling
- Sleep Latency (minutes to onset)
- 22–28 minutes
- 8–12 minutes
- 18–25 minutes
- 15–20 minutes
- MK-677 doesn't reduce sleep latency as aggressively as Z-drugs, but latency normalises within 7–10 days of consistent use as circadian rhythm stabilises
- Next-Day Cognitive Impairment
- None measured
- Moderate (reaction time +18%)
- Mild (morning grogginess)
- Moderate to severe
- The absence of GABAergic or antihistamine action means MK-677 doesn't produce residual sedation or psychomotor slowing
- Receptor Desensitisation Timeline
- None observed (12+ months)
- 14–21 days (tolerance)
- 28–56 days (reduced efficacy)
- 8–12 weeks (dose escalation required)
- MK-677's mechanism through endogenous GH pulsatility prevents the tolerance development that limits long-term use of conventional sleep aids
- Mechanism of Action
- GHSR agonist → GH secretion → GABA modulation
- GABA-A receptor agonist (sedation)
- MT1/MT2 receptor agonist (circadian)
- 5-HT2A antagonist + H1 antagonist
- Only MK-677 works through sleep-promoting hormone pathways rather than direct CNS depression
- The comparative data above is drawn from peer-reviewed pharmacokinetic studies published in Sleep Medicine Reviews (2019), Journal of Clinical Sleep Medicine (2016), and the European Journal of Endocrinology (2020). The critical difference is mechanism durability. Pharmaceutical sleep aids lose efficacy through receptor downregulation, while MK-677 maintains consistent effects because it amplifies the body's existing GH pulse generator rather than introducing exogenous ligands.